PMGC Secures Five-Year Royalty Stream from Elevai Skincare Sale
ELAB is trading near its 52-week low of $4.401 (6.8% above the low).
Summary
PMGC Holdings has converted its contingent earnout from the January 2025 sale of Elevai Skincare into a contractual, interest-bearing payment stream. Longevity Health Holdings acknowledged a $94,937 royalty obligation for 2025, with monthly installments of $10,000 starting October 15, 2026, and all amounts due by August 2031. The agreement adds 15% mandatory prepayments from qualifying capital raises and asset sales, plus audit rights and acceleration on default. This provides PMGC with visible, non-dilutive cash flow while retaining upside from the five-year 5% royalty on Elevai product sales. The company has been navigating a going concern warning and dilutive financing, so this structured receivable is a modest but tangible liquidity improvement.
At the time of this announcement, ELAB was trading at $4.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $4.40 to $2,671.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.